Levodopa Market to Reach $2.9 Billion Globally By 2032 at 6.1% CAGR: Allied Market Research
The increasing prevalence of Parkinson’s disease, rising healthcare expenditure, and technological advancements in drug delivery are projected to drive the global levodopa market’s growth during the forecast period.
Global Parkinson’s Disease Market for Spectacular Growth, Projected to Reach US$ 6.1 Billion by 2033 with a 5.1% CAGR
The global Parkinson’s Disease market is projected to be valued US$ 3.7 billion. The global market is anticipated to expand at a consistent 5.1% CAGR between 2023 and 2033, culminating in a valuation of US$ 6.
Cerevel Therapeutics, which AbbVie is acquiring, said Thursday its drug tavapadon, taken with the common Parkinson's drug ...
A one-time treatment for Parkinson’s disease could be a ‘market changer,’ experts told BioSpace, adding that cell therapies ...
A student team in the Department of Biomedical Engineering has developed a signal processing algorithm that they hope will ...
Cerevel Therapeutics’ Parkinson’s disease therapy tavapadon has shown efficacy in a phase 3 trial, reinforcing its ...
Cerevel Therapeutics on Thursday reported positive data from its Phase III TEMPO-3 trial, showing that tavapadon can ...
1d
Michael J. Fox posed for photographs alongside his wife Tracy Pollan on the red carpet at the glitzy Time 100 Gala in New ...
Lucknow: Challenging one’s brain is one of the most effective ways to stay away from Parkinson’s disease, according to ...
Cerevel Therapeutics said its Parkinson's disease drug improved symptom control in patients when tested as an add-on therapy, ...
A late-stage trial of Cerevel Therapeutic’s Parkinson’s disease drug showed a significant reduction in the time patients suffer from symptoms, the company said Thursday, the latest study indicating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback